✦ LIBER ✦

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

✍ Scribed by Robert Pirker; Jose R Pereira; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Keunchil Park; Filippo de Marinis; Wilfried EE Eberhardt; Luis Paz-Ares; Stephan Störkel; Karl-Maria Schumacher; Anja von Heydebreck; Ilhan Celik; Kenneth J O'Byrne

Book ID: 117785840
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 872 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70318-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-cycle rash and survival in patient

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

✍ Ulrich Gatzemeier; Joachim von Pawel; Ihor Vynnychenko; Petr Zatloukal; Filippo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 220 KB

A phase II study of carboplatin and pacl

A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)

✍ Giorgio, Carmelo Giannitto; Pappalardo, Alessandro; Russo, Antonio; Giuffrida, D 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

PCN43 THE COST OF TREATING GRADE 3/4 ADV

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

✍ C Chouaid; A Vergnenegre; M Brunner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

First line chemotherapy with gemcitabine

First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule

✍ Quoix, Elisabeth; Breton, Jean-Luc; Ducoloné, Alain; Mennecier, Bertrand; Depier 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 155 KB